Form 4: Lexeo Therapeutics Executive Sandi See Tai Reports Acquisition of Common Stock

Sandi See Tai, Chief Development Officer of Lexeo Therapeutics, reports acquiring 5,720 shares of common stock through the company's Employee Stock Purchase Plan.

Summary

• On March 14, 2025, Sandi See Tai, Chief Development Officer of Lexeo Therapeutics, acquired 5,720 shares of Lexeo Therapeutics common stock.
• The shares were purchased at a price of $2.61 per share through the company's 2023 Employee Stock Purchase Plan.
• Following the transaction, Tai directly owns 59,609 shares of Lexeo Therapeutics common stock, which includes 51,218 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by an executive is generally viewed as a positive sign, but the transaction is part of a routine employee stock purchase plan and doesn't necessarily indicate a major shift in sentiment.

Positives

• The acquisition of shares by a company executive can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide investors with insights into the buying and selling activities of company executives and directors, which can influence investor sentiment.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder confidence due to the executive's increased investment in the company.

Key Dates

Keywords

Lexeo Therapeutics, Sandi See Tai, Form 4, Beneficial Ownership, Employee Stock Purchase Plan, LXEO, Common Stock, Restricted Stock Units